Kaytee Bio, Co.&Ltd. is a biotech company incorporated and operating in Japan. We aim at overcoming diseases by developing and applying brand new diagnostic technology and drugs. We have developed a differentiated technology using short-talin to diagnose and treat RA. Our patent-protected technology allows exact diagnosis of RA at the early stage and monitoring of RA treatment. Another our powerful technology is the prediction of biologics treatment of RA based on the baseline blood ADAMTS5 mRNA expression. Efficacy of infliximab, etanercept, adalimumab, tocilizumab, and abatacept can be predictive using the “BiologicMate®” of this ADAMTS5 system. We’ve discovered the short-talin was expressed specifically in the peripheral blood obtained from RA patients. This short-talin has been thought to induce the activation and extra-vascular migration of T cells followed by the bone destruction with cytokine production. The new therapeutic procedures have been developed based on the research that the regulation of this short-talin is the key of RA treatment.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.